RxDoctor Payments Data

Seung Kim, MD

Geriatric Medicine · Los Angeles, CANPI 1134153653

Payments from drug & device makers

$317in general payments, 2019–2025

Across 11 payments — averaging $28.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$113
  • AbbVie$45
  • Pfizer$35
  • IBSA Pharma Inc.$34
  • Mannkind Corporation$30
  • GSK$25
  • plus $35 from 2 others

What the payments were for

  • Food & beverage$28289%
  • Education$3511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$317 in reported general payments places this provider in the 60th percentile of 494 geriatric medicine providers in California.

See all geriatric medicine providers in California

Medicare billing

Part B allowed, 2024
$84,456
Medicare patients
208
Services billed
1,513

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase392$427,182
VascepaIcosapent Ethyl620$263,786
JanuviaSitagliptin Phosphate280$257,107
FarxigaDapagliflozin Propanediol100$96,157
TradjentaLinagliptin100$91,183
JardianceEmpagliflozin56$53,608
RestasisCyclosporine66$53,190
ProliaDenosumab31$51,396
LinzessLinaclotide48$48,698
ZenpepLipase/Protease/Amylase50$40,544
Diclofenac Epolamine89$33,536
MyrbetriqMirabegron38$30,987
JanumetSitagliptin Phos/Metformin Hcl29$24,812
Cyclosporine56$24,651
OzempicSemaglutide17$22,323

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Restasis, Linzess$45$529,070506 claims
PfizerEliquis, Paxlovid$35$24,35479 claims
GSKShingrix, Breo Ellipta$25$19,74887 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 494 geriatric medicine providers in California.

Other geriatric medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →